Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

NCT02477267
View directory record Official record
Conditions
Opiate Dependence
Interventions
SL spray, SL film
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171
View directory record Official record
Conditions
Heroin Dependence, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02310581
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine Sublingual Spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Open-Label, Safety Study of Lofexidine

NCT02363998
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Lofexidine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Springdale, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Buprenorphine on Responses to Verbal Tasks

NCT01860287
View directory record Official record
Conditions
Basic Science
Interventions
Buprenorphine 0.2 MG Sublingual Tablet, Placebo, Buprenorphine 0.4 MG Sublingual Tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Using Clinical Decision Support to Provide Social Risk-Informed Care for Opioid Use Disorder in the Emergency Department

NCT06872190
View directory record Official record
Conditions
Opioid Use Disorder, Social Determinants of Health (SDOH)
Interventions
ED-Based Clinical Decision Support for Opioid Use Disorder, Social Care-Enhanced Clinical Decision Support for Opioid Use Disorder
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Withdrawn Not applicable Interventional

Use of Transcranial Magnetic Stimulation to Reduce Craving for Individuals With Opioid Use Disorder Taking Buprenorphine

NCT03653169
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

NCT04360681
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Lofexidine, Placebo oral tablet
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments

NCT03821103
View directory record Official record
Conditions
Opioid Use
Interventions
Training, Behavioral economic enhanced arm
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Rapid Initiation of Drug Treatment Engagement

NCT03908437
View directory record Official record
Conditions
Opioid-use Disorder, Overdose
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 28, 2026, 5:38 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

NCT00000329
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine's Dose Response Curve

NCT00460239
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine, Morphine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

NCT00320801
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
66
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Collaborating to Heal Addiction and Mental Health in Primary Care

NCT04600414
View directory record Official record
Conditions
Opioid-use Disorder, Mental Health Disorder
Interventions
Collaborative Care for Mental Health Symptoms, Collaborative Care for Opioid Use Disorder and Mental Health Symptoms
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
33
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Dunwoody, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Buprenorphine Detox With Two Types of Treatment. BBD I - 10

NCT00000228
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 28, 2026, 5:38 AM EDT
Completed No phase listed Observational

Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics

NCT02863601
View directory record Official record
Conditions
Opiate Addiction, Pregnancy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 5:38 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 28, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional

Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder

NCT04257214
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psychosocial treatment
Behavioral
Lead sponsor
Philadelphia College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Atlantic City, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Enhancing Addiction Treatment Through Psychoeducation

NCT07178158
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Installing the Metacognium software app, Continue treatment as usual
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

Optimal Treatment of Veterans With PTSD and Comorbid OUD

NCT03605342
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Opiate Use Disorder
Interventions
Buprenorphine, Cognitive Processing Therapy (CPT), Individual Drug Counseling (IDC)
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
West Haven, Connecticut • Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 28, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 28, 2026, 5:38 AM EDT